Introduction
Multifocal motor neuropathy (MMN) and progressive muscular atrophy (PMA) share clinical characteristics of progressive muscle weakness and atrophy. MMN is an immune-mediated neuropathy characterized by nerve conduction block and is amenable to treatment with intravenous immunoglobulin (IVIg) (Vlam et al., 2011) . PMA is a heterogeneous neurodegenerative disorder with a natural history ranging from rapidly progressive with ensuing respiratory insufficiency within years to slowly progressive in decades (Van den Berg-Vos et al., 2009; Visser et al., 2007) . The association of IgM anti-GM1 antibodies with MMN is well established and these antibodies can be detected in approximately 50% of patients (Cats et al., 2010) . We recently found that both MMN and PMA, but not amyotrophic lateral sclerosis (ALS), were associated with IgM monoclonal gammopathy and high titers of IgM anti-GM1 antibodies were also present in 11% of patients with PMA (Vlam et al., 2015) . Moreover, patients with PMA and IgM monoclonal gammopathy and/or high IgM anti-GM1 antibodies tended to have a more favorable disease course (Vlam et al., 2015) . The presence of IgM monoclonal gammopathy and IgM anti-GM1 antibodies in patients with MMN and a subgroup of PMA may suggest common pathogenic mechanisms, in particular the activation of specific B-cells.
The aim of this study was to further investigate the role of B-cells in the pathogenesis of MMN and PMA. We therefore determined circulating protein concentrations relevant for B-cell function in serum of patients with MMN and PMA with and without IgM monoclonal gammopathy or IgM anti-GM1 antibodies, patients with ALS and healthy controls.
Methods

Patients and controls
We included 55 patients with PMA of whom 14 (25%) had an IgM monoclonal gammopathy or IgM anti-GM1-antibodies (PMA +), 25 patients with MMN of whom 14 (56%) had an IgM monoclonal gammopathy or IgM anti-GM1-antibodies, 25 patients with ALS and a total of 50 healthy controls. Sera with IgM anti-GM1-antibodies of 1:400 or higher were considered positive since these high antibody titers are known to be specifically associated with MMN whereas lower antibody titers can occasionally also be found in sera from healthy controls (Cats et al., 2010) . The healthy controls were age and gender matched to the corresponding disease phenotype. Diagnostic criteria were described previously (Vlam et al., 2015) . Demographic features, clinical characteristics and survival were recorded. Exclusion criteria for patients and controls included diabetes mellitus, since high blood glucose levels induce cytokine release (Gonzalez et al., 2012; Shanmugam et al., 2003) and IVIg treatment less than six months prior to blood sampling, since IVIg is known to modulate cytokine production (Andersson et al., 1996; Murakami et al., 2012) . Since cytokine levels decrease after multiple freeze-thaw cycles and cytokines are known to degrade over time, especially when storage time exceeds three years (de Jager et al., 2009), we selected recently collected serum samples and used samples that had not been thawed before. Moreover, the serum samples of the healthy controls were matched for freezer storage time to the PMA, ALS and MMN samples.
The Medical Ethical Committee of the University Medical Center Utrecht approved the study protocol and all subjects gave written informed consent.
Cytokine assays
B-cell activating factor (BAFF), a proliferation inducing ligand (APRIL), interleukin 2 (IL-2), IL-4, IL-6, IL-7, IL-8, IL-10, IL-12, IL-21, tumor necrosis factor α (TNF-α), interferon α (IFN-α), IFN-γ, granulocyte colonystimulating factor (G-CSF), chemokine (C-X-C motif) ligand 13 (CXCL 13) and vascular endothelial growth factor (VEGF) were selected as the inflammatory markers of interest (Acosta-Rodriguez et al., 2007; Crampton et al., 2010) . BAFF and APRIL concentrations were determined using a standardized pre-coated enzyme-linked immunosorbent assay (ELISA) (eBioscience, Vienna, Austria) according to the manufacturer's instructions. The remaining proteins were measured by an in house developed and validated panel using xMAP technology (Luminex, Austin, TX USA) as described previously (de Jager et al., 2007) . Acquisition was done with xPonent 4.2 (Luminex) and analysis with Bioplex manager 6.1.1 (Biorad Laboratories, Herfordshire, UK).
Statistical analysis
Chi-square test or Mann-Whitney U test was used to investigate differences in gender and age between patients and controls. Cytokine concentrations in the patient groups and controls were compared with Mann-Whitney U test (SPSS for Windows, Chicago, IL USA). A p-value b0.05 was considered statistically significant. To investigate whether a single cytokine contributed to disease susceptibility a cluster analysis was performed (Omniviz v6.1 Instem scientific, Staffordshire, UK).
Results
Patients and controls
Baseline characteristics are shown in Table 1 . Median age and gender did not differ between patients with PMA +, PMA −, ALS and controls, and between MMN patients and matched controls. Nerve conduction studies in patients with MMN showed a probable (compound muscle action potential (CMAP) area reduction of 30-50% in an arm nerve) (12%) or definite (area reduction of at least 50%) (88%) conduction block (Van Asseldonk et al., 2003) . Only two MMN patients had no signs of axon loss, defined as normal distal CMAP amplitudes of the median, ulnar, radial, musculocutaneous, peroneal, and tibial nerves on both sides (Van Asseldonk et al., 2003) . Serum of 12 MMN patients (50%) contained IgM anti-GM1 antibodies with titres ≥ 1:400 and 2 MMN patients had a detectable IgM monoclonal protein. Of the PMA patients, 7 had a IgM monoclonal gammopathy, 3 patients had high IgM anti-GM1 antibodies and 4 patients had both. Fig. 1 . Heatmap of cytokine profiles. Heatmap was made with the diagnosis fixed. The black bar represents the 14 PMA+ patients, the gray bar the 25 MMN patients and the white bar the 50 healthy controls. A color profile was made to show the cytokine profile of each individual using minimal and maximal expression normalization per protein; red represents a maximum and blue a minimum cytokine concentration (all pg/ml). There was no clustering of any of the tested cytokines among the patient subgroups. 
Cytokine levels
None of the tested median serum protein levels were significantly elevated in patients with MMN or patients with PMA and IgM monoclonal gammopathy or high IgM anti-GM1 antibodies compared to healthy and disease controls. A heatmap of all markers is displayed in Fig. 1 . Hierarchical cluster analysis of the different cytokines for the MMN patients, PMA+ patients and healthy controls revealed no significant clusters (data not shown). Cytokine profiles between MMN patients with and without IgM anti-GM1 antibody titres ≥1:400 did not differ. Because the IL-6 concentration tended to be slightly higher in the PMA+ patients (Fig. 2) , we performed a sub-analysis comparing the 2 MMN and 11 PMA patients with IgM monoclonal gammopathy combined to the PMA matched healthy controls. There was no difference in median IL-6 levels between the subgroups (4.8 vs 3.0 p = 0.2). We could not corroborate findings of increased IL-2, TNF-α and G-CSF levels (Furukawa et al., 2014; Terenghi et al., 2006) (Fig. 2) .
Discussion
We recently reported the association of IgM monoclonal gammopathy with both MMN and PMA (Vlam et al., 2015) , suggesting that similar disease mechanisms may underlie these disorders. In this study we investigated whether concentrations of specific cytokines that are associated with B-cell function are increased in serum from patients with MMN and PMA. We applied strict selection criteria for the used serum samples and matched our controls for age and gender to our patients to reduce the possibility of spurious associations (Andersson et al., 1996; de Jager et al., 2009; Gonzalez et al., 2012; Murakami et al., 2012; Shanmugam et al., 2003) . We did not find significant differences in any of the 16 tested cytokine levels between the patient groups and healthy controls.
Our findings are in line with the study by Terenghi et al. who also found comparable cytokine concentrations in 22 patients with MMN and healthy controls (Terenghi et al., 2006) , but contradict recent finding by others, who reported elevated serum IL-1Ra, IL-2, G-CSF, TNF-a, and TNFR1 levels in 16 patients with MMN compared to 15 patients with other non-inflammatory neurological diseases (Furukawa et al., 2014) . They also found significantly increased levels of G-CSF and TNF-a in patients with MMN compared to patients with ALS, and in the 11 MMN patients with 'focal demyelination' (Furukawa et al., 2014) . Serum TNF-a levels in the MMN patients with decreased distal CMAP amplitudes tended to be higher than those in the nondecreased CMAP group (Furukawa et al., 2014) . All of our included MMN patients -in line with diagnostic consensus criteria -had conduction block, i.e. focal demyelination, and only two patients had no signs of axonal loss. We were therefore unable to corroborate the previously reported results, although it seems unlikely that the presence of focal demyelination can be explained by the presence of specific cytokines.
Our study does not provide evidence for a systemic B-cell mediated immune response in MMN and PMA+, as has been reported in other inflammatory neurological disorders such as multiple sclerosis, optic neuromyelitis and anti-MAG neuropathy. We cannot exclude the possibility that MMN and PMA are different from these prototypical neurological inflammatory disorders, in the sense that they are characterized by very localized, low-grade inflammatory processes. This may ultimately damage motor neurons or axons, but may not be reflected in increased systemic cytokine levels. Alternatively, the presence of monoclonal gammopathy may be secondary to other disease mechanisms such as increased motor neuron and axon loss, although we find this less likely since we did not find an increased prevalence of monoclonal gammopathy in patients with ALS (Vlam et al., 2015) . 
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